Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in Stage I low‐risk trophoblastic neoplasia

Abstract

Among patients who are candidates for second-line treatment on the basis of hCG, ultrasound may identify those in whom further MTX administration can induce a delayed complete response.